ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Synergistic effect of canine FGF-21 combined with insulin in the treatment of canine diabetes.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Previous studies have shown that FGF-21 can ameliorate hyperglycemia and improve the level of oxidative stress in vivo in diabetic mice. The hypoglycemic effect is safe and lasting, but it takes a longer time to exert its effect. Insulin treatment of canine diabetes takes effect quickly; however, its action time is short, and it is prone to cause hypoglycemia. In the present study, we investigated the synergistic effect of cFGF-21 combined with insulin in the treatment of canine diabetes. In the short and long-term treatment of diabetic dogs, cFGF-21 combined with insulin showed an obvious synergistic effect, and its hypoglycemic effect was significantly better than that of cFGF-21 or insulin injection alone. The combination, exhibited the advantage of the fast onset of insulin and the long-term hypoglycemic effect of cFGF-21. Additionally, cFGF-21 combined with insulin effectively relieved the oxidative stress in diabetic dogs. Studies of the synergistic mechanism showed that cFGF-21 combined with insulin could effectively inhibit liver gluconeogenesis and the synthesis of long-chain fatty acids and promote the phosphorylation of the common factor AKT in the pathway to better regulate hyperglycemia in diabetic dogs. In conclusion, cFGF-21 combined with insulin is a promising candidate for canine diabetes therapeutics.
Indexed as
Identifiers
39836254What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.